Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1206-1208, 2003; 10.1373/49.7.1206
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yagihashi, A.
Right arrow Articles by Watanabe, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yagihashi, A.
Right arrow Articles by Watanabe, N.
Related Collections
Right arrow Clinical Immunology
Right arrow Cancer Diagnostics (since 2002)
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2003;49:1206-1208.)
© 2003 American Association for Clinical Chemistry, Inc.

Technical Briefs

Detection of Anti-Livin Antibody in Gastrointestinal Cancer Patients

Atsuhito Yagihashi1, Koichi Asanuma1, Naoki Tsuji1, Toshihiko Torigoe2, Noriyuki Sato2, Koichi Hirata3 and Naoki Watanabe1,a

Departments of
1 Clinical Laboratory Medicine,
2 Pathology, and
3 Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo 060-8543, Japan

aauthor for correspondence: fax 81-11-622-7502, e-mail watanabn@sapmed.ac.jp

The first 300 words of the full text of this article appear below.

Livin, a recently described member of the inhibitor of apoptosis protein (IAP) family, contains a single baculovirus IAP repeat and a carboxyl-terminal RING finger (1)(2)(3). Like other proteins in the IAP family, livin binds specifically to a terminal effector cell-death protease, in this instance, caspase-9 (1)(2)(3). The consequences are substantially reduced caspase activity and reduced cell death in response to diverse apoptotic stimuli (1)(2)(3). Semiquantitative reverse transcription-PCR methods have detected human livin mRNA in fetal kidney, heart, and spleen and in adult tissues such as heart, lung, spleen, ovary, and placenta (4). In addition, livin mRNA is overexpressed by some cancer cells, including melanoma, breast cancer, cervical cancer, colon cancer, prostate cancer, leukemia, and lymphoma cells (4).

As with survivin overexpression (5)(6)(7), livin overexpression by cancer cells may lead to anti-livin antibody responses and cytotoxic T-lymphocyte responses against the cancer. In the present study, we examined livin mRNA expression in gastrointestinal cancer cell lines and the prevalence of antibody responses against livin in patients with various gastrointestinal cancers.

We cultured human pancreatic cancer cell lines (PANC-1, Capan-1, AsPC-1, MIAPaCa-2, and BxPC-3), gastric cancer cell lines (MKN-1, MKN-45, and TMK-1), colon cancer cell lines (HT-29, SW480, SW620, and LSI180), and a hepatoma cell line (HepG2) in RPMI-1640 with 100 mL/L calf serum at 37 °C in 5% CO2. Livin mRNA expression was quantified by a previously reported method (8). The sequence of the forward primer was 5'-TCAGTTCCTGCTCCGGTCA-3', that the reverse primer was 5'-CGTCTTCCGGTTCTTCCCA-3', and the sequence of the TaqMan probe was 5'-CCACAGTGTGCAGGAGACTCACTCCC-3'. As an internal control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA was used and amplified with TaqMan control reagents (Perkin-Elmer Applied . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
E. Sato, T. Torigoe, Y. Hirohashi, H. Kitamura, T. Tanaka, I. Honma, H. Asanuma, K. Harada, H. Takasu, N. Masumori, et al.
Identification of an Immunogenic CTL Epitope of HIFPH3 for Immunotherapy of Renal Cell Carcinoma
Clin. Cancer Res., November 1, 2008; 14(21): 6916 - 6923.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Vucic and W. J. Fairbrother
The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer
Clin. Cancer Res., October 15, 2007; 13(20): 5995 - 6000.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Chang and A. D. Schimmer
Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy
Mol. Cancer Ther., January 1, 2007; 6(1): 24 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Takeuchi, J. Kim, A. Fujimoto, N. Umetani, T. Mori, A. Bilchik, R. Turner, A. Tran, C. Kuo, and D. S.B. Hoon
X-Linked Inhibitor of Apoptosis Protein Expression Level in Colorectal Cancer Is Regulated by Hepatocyte Growth Factor/C-Met Pathway via Akt Signaling
Clin. Cancer Res., November 1, 2005; 11(21): 7621 - 7628.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Hariu, Y. Hirohashi, T. Torigoe, H. Asanuma, M. Hariu, Y. Tamura, K. Aketa, C. Nabeta, K. Nakanishi, K. Kamiguchi, et al.
Aberrant Expression and Potency as a Cancer Immunotherapy Target of Inhibitor of Apoptosis Protein Family, Livin/ML-IAP in Lung Cancer
Clin. Cancer Res., February 1, 2005; 11(3): 1000 - 1009.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.